在患有骨质疏松症的患者中,PTH/PTHrP类似物作为骨质代谢治疗
Enrique Casado1, Guillermo Martínez-Díaz-Guerra2, José Ramon Caeiro3
1Servicio de Reumatología, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona (UAB), Sabadell, Barcelona, España.
特里巴拉提德和阿巴洛巴拉提德是有效的骨质疏松症治疗方法. 与teriparatide相比,阿巴洛帕拉提德通过刺激较少的再吸收,为皮层骨提供了更大的益处.
科学领域:
- 内分泌学和骨生物学 骨生物学
- 骨质疏松症的药理学 治疗药物
背景情况:
- 绝经后骨质疏松症 (PMO) 具有显著的骨折风险,需要有效的治疗.
- 甲状腺激素 (PTH) 的类似物,包括特里巴拉提德 (TPTD) 和阿巴洛巴拉提德 (ABL),推用于高风险患者.
- 无论是TPTD还是ABL,都准PTH受体1 (PTHR1),影响骨重塑.
研究的目的:
- 为了比较 teriparatide 和 abaloparatide 对骨重塑的不同作用.
- 阐明TPTD和ABL触发的差异信号响应,尽管它们对相同的受体起作用.
- 突出这些差异对治疗严重的绝经后骨质疏松症的临床影响.
主要方法:
- 对 teriparatide 和 abaloparatide 的药理作用进行比较分析.
- 对减少骨折风险和改善骨微型架构的现有临床数据的审查.
- 检查通过 PTHR1.1.通过 TPTD 和 ABL 激活的下游信号通路.
主要成果:
- 特里巴拉提德和阿巴洛巴拉提德都显示出显著的骨代谢作用,并改善骨微型结构.
- 与teriparatide相比,阿巴洛帕拉提德对骨再吸收的刺激较小.
- 这些差异性影响导致阿巴洛帕拉提德治疗对皮质骨的益处更大.
结论:
- 特里巴拉提德和阿巴洛巴拉提德是治疗严重的绝经后骨质疏松症的有效一线治疗方法.
- 阿巴洛帕拉提德减少了骨质再吸收的刺激,为皮层骨健康提供了明显的优势.
- 了解差异信号是优化骨质疏松症治疗的关键.
更多相关视频
11:47A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
07:53Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects
Published on: December 10, 2010
相关概念视频
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Bone Remodeling
Osteoclasts in Bone Remodeling
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
